Abstract The purpose of this study was to assess the prognostic and predictive value of tumor-infiltrating lymphocytes (TILs) in the triple-negative breast cancer (TNBC) cohort of the phase III IBCSG trial 22-00, comparing lowdose oral 'metronomic' cyclophosphamide-methotrexate maintenance chemotherapy (CM-maintenance) to no-CMmaintenance in early breast cancer. TILs were evaluated in full-face hematoxylin-and-eosin-stained sections of tumor samples confirmed centrally as TNBC (\ 1 % of ER and PgR immunoreactivity and absence of HER2 overexpression or amplification). Mononuclear cells were evaluated in the stromal area within the borders of the invasive tumor. The primary endpoint was breast cancer-free interval (BCFI).
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Abstract The purpose of this study was to assess the prognostic and predictive value of tumor-infiltrating lymphocytes (TILs) in the triple-negative breast cancer (TNBC) cohort of the phase III IBCSG trial 22-00, comparing lowdose oral 'metronomic' cyclophosphamide-methotrexate maintenance chemotherapy (CM-maintenance) to no-CMmaintenance in early breast cancer. TILs were evaluated in full-face hematoxylin-and-eosin-stained sections of tumor samples confirmed centrally as TNBC (\ 1 % of ER and PgR immunoreactivity and absence of HER2 overexpression or amplification). Mononuclear cells were evaluated in the stromal area within the borders of the invasive tumor. The primary endpoint was breast cancer-free interval (BCFI).
Cox proportional hazards regression model assessed the association of BCFI and secondary endpoints with TILs score. In the 647 tumor samples, the median percentage of TILs was 18 % (IQR = 8-40 %), with 18 % having TILs C 50 % (lymphocyte-predominant breast cancer, LPBC). At a median follow-up of 6.9 years, TILs were associated with better prognosis. For every 10 % increase of TILs, BCFI risk reduction was 13 % (HR 0.87, 95 % CI 0.79-0.95,P = 0.003). DFS, DRFI, and OS risk reductions were 11 % (P = 0.005), 16 % (P = 0.003), and 17 % (P \ 0.001), respectively. Multivariable analysis confirmed the independent prognostic value of TILs. No significant TILs-by-treatment interaction was observed (P = 0.39) for associations of TILs with BCFI, although patients with LPBC receiving CM-maintenance had a greater breast cancer risk reduction (HR 0.64,95 % CI 0.23-1.78) than those with non-LPBC (TILs \ 50 %) (HR 0.96, 95 % CI 0.67-1.40). TILs score is a potent prognostic factor in
Introduction
Tumor-infiltrating lymphocytes (TILs) are associated with a favorable prognosis in breast cancer patients, especially among women with triple-negative breast cancer (TNBC) [1] [2] [3] [4] [5] . Since the seminal work by Loi et al. [1] , several groups, including our own [5] , demonstrated a positive linear correlation between TILs and breast cancer-specific survival. Furthermore, we recently confirmed the validity of the TILs assessment guidelines in the clinical setting [5] , and the International TILs working group (TILs WG) [6] has carried out ring studies for improving decentralized TILs scoring reproducibility [Denkert et al. JAMA Oncol, submitted] . These data unequivocally indicate that TILs may soon enter the clinical arena as a novel prognosticator for patients with TNBC. Nevertheless, there is no convincing evidence that TILs predict sensitivity to different chemotherapy regimens. Most available reports are in patients treated with anthracycline-containing chemotherapy regimens [1] [2] [3] , although we recently reported that each 10 % increase of TILs conferred a significant risk reduction also in patients treated with cyclophosphamide, methotrexate, and fluorouracil (CMF) [5] .
Preclinical and clinical studies support the notion that non-toxic, low-dose continuous chemotherapy with cyclophosphamide and methotrexate (CM-maintenance) is of clinical value in TNBC [7] [8] [9] [10] . In the present study, we evaluated TILs in patients with TNBC enrolled in the randomized, phase III International Breast Cancer Study Group (IBCSG) Trial 22-00, testing the efficacy of lowdose oral CM-maintenance following standard adjuvant chemotherapy treatment for hormone receptor-negative breast cancer patients.
Trial 22-00 reported a nonsignificant reduction of the relative risk of recurrence in patients with TNBC treated with CM-maintenance, suggesting that this schedule may be a reasonable therapeutic option, also considering its low cost and tolerability [10] . In this study, we evaluated the prognostic value of TILs in the largest phase III randomized TNBC cohort reported to date, and the interaction of TILs with low-dose maintenance chemotherapy.
Patients and methods

Patients and samples
International Breast Cancer Study Group Trial 22-00 is a multi-center, randomized, adjuvant phase III trial comparing low-dose CM-maintenance (cyclophosphamide 50 mg/day orally continuously for 1 year and methotrexate 2.5 mg/twice a day orally, days 1 and 2 of every week for 1 year) to no maintenance chemotherapy (No-CM), following breast cancer surgery and standard induction chemotherapy [10] . The trial recruited 1081 patients with estrogen (ER) and progesterone (PgR) receptor-negative Meredith M. Regan mregan@jimmy.harvard.edu Marco Colleoni marco.colleoni@ieo.it tumors, and any HER2 and nodal status. For the present study, we limited our analysis to patients with tumors confirmed centrally as TNBC (\ 1 % of ER and PgR immunoreactivity and absence of HER2 overexpression or amplification) [11] . ER and PgR assessments used the ER/ PgR PharmDX kits, Dako, and HER2 status was assessed using the immunohistochemistry with the HercepTest, Dako, and FISH with PathVysion HER2 DNA probe kit, Vysis-Abbott, when necessary [12] . In addition, the IBCSG Central Pathology Office re-evaluated tumor type and grade, and Ki-67 labeling index (MIB-1 monoclonal antibody, 1:200) [12] [13] [14] . The eligibility criteria for Trial 22-00 excluded patients with history of previous malignancies (except for primary skin cancer) and prior neoadjuvant therapy for breast cancer. Patients in the analytic cohort consented to use of their tumor tissue for research purposes, and the project was approved by the IBCSG biological protocols working group.
The analysis of TILs was retrospectively performed in full-face hematoxylin and eosin sections, strictly adhering to the criteria proposed by the TILs WG [6] . In brief, all mononuclear cells (i.e., lymphocytes and plasma cells) in the stromal compartment within the borders of the invasive tumor were evaluated and reported as a percentage (TILs score). TILs outside of the tumor border, around DCIS and normal breast tissue, as well as in areas of necrosis, if any, were not included in the scoring. Tumors with TILs score of C 50 % were considered lymphocyte-predominant breast cancer (LPBC). TILs were assessed both as a continuous measure (score) and as a dichotomous measure (LPBC vs. non-LPBC).
Statistical analysis
The primary endpoint was breast cancer-free interval (BCFI), defined as the time from randomization to the recurrence of invasive breast cancer (local, regional, or distant) or invasive contralateral breast cancer. Secondary endpoints included disease-free survival (DFS): time from randomization to the first appearance of invasive recurrence of breast cancer (local, regional, or distant), invasive contralateral breast cancer, second (non-breast) invasive cancer, or death without prior cancer event; distant recurrence-free interval (DRFI): time from randomization to the recurrence of breast cancer at a distant site; and overall survival (OS): time from randomization to death from any cause. In the absence of BCFI, DFS, DRFI, or OS events, endpoints were censored at the date of last follow-up or known alive.
Cox proportional hazards regression models [15] were stratified by menopausal status and type of induction chemotherapy, and assessed the associations of BCFI, DFS, DRFI, and OS with TILs and estimated the hazards ratio (HR) and 95 % confidence interval (CI). Multivariable models included age at randomization:\40, 40-49, 50-59, C60 years; lymph node status: N0, N ? 1-3, N ? C 4; tumor size: B2, [2 cm; and tumor grade: 1-2, 3.
The distribution of study endpoints according to TILs (LPBC vs. non-LPBC) was estimated using the KaplanMeier method [16] . The predictive role of TILs was investigated by including the TILs (LPBC)-by-treatment interaction term in the Cox model. Subpopulation Treatment Effect Pattern Plot (STEPP) [17] analysis was also used to explore the relationship between TILs score along the continuum and 5-year BCFI percentages for the two treatment groups.
With an analytic cohort of 647 patients (Fig. 1 ), assuming 18 % of patients with LPBC, the cohort would have 81 % power (two-sided type I error of 0.05) to detect a HR of 0.52 comparing LPBC versus non-LPBC. Treatment-by-TILs (LPBC) interaction was tested using Cox models with 1-df Wald test. With our LPBC and breast cancer event distributions, there was 70 % power to detect an interaction hazard ratio of 0.44 (treatment HR (0.47) for LPBC relative to treatment HR (0.95) for non-LPBC) using large sample approximation. Therefore, the statistical power for treatment-by-TILs (LPBC) interaction is likely limited, so inference regarding differential treatment effects should be interpreted with caution.
Associations between the TILs as a continuous variable and patient and disease characteristics were evaluated using the Wilcoxon test (two groups comparison) or Kruskal-Wallis test ([2 groups comparison).
All analyses were pre-specified and followed the reporting recommendations for tumor marker prognostic studies criteria (REMARK) [18] . Two-sided P values were reported for all analyses. To assess the analytic validity of the TILs score, a subset of 70 (*10 % of the analysis cohort) samples was independently read by two pathologists, and the interobserver correlation was measured as the proportion with scores within ± 10 points, with exact binominal CI.
Results
Patients
After routine central assessment of ER, PgR, and HER2 in Trial 22-00, 724 samples were identified as TNBC. TILs were evaluated from 672 tumors with adequate submitted tissue and consent, and 25 specimens could not be assessed, resulting in the analysis cohort of 647 patients, 340 assigned to CM-maintenance and 307 to No-CM (Fig. 1) . Characteristics of the analytic cohort are shown in Table 1 . The median follow-up was 6.9 years (95 % CI 6.6-7.2), and median age was 52 years (interquartile range (IQR) 44-59), with 45 % of the patients being premenopausal at the study entry. Breast-conserving surgery was performed in 79 %, and the axillary lymph node status was N0 in 57 % of the patients. Induction chemotherapy regimens included anthracyclines for 83 % of patients.
Distributions of TILs and associations with clinicopathological characteristics
The median TILs score was 18 % (IQR 8-40 %) ( Table 1) . TILs score distributions according to treatment, age, nodal status, tumor grade, and tumor size are shown in Fig. 2 . In the assessment of stromal lymphocytic infiltration, the two pathologists had an agreement rate of 96 % (95 % CI 88-99 %), and no evidence of bias was found in the BlandAltman plot (data not shown). Patients with grade 3 had a higher median TIL score (20 %, IQR 8-40 %) than those with grade 1 or 2 (8 %, IQR 5-16 %); younger patients (age 23-\40) had the highest median TIL score (26 %, IQR 10-52 %) compared with patients aged 40-\50 (20 %, IQR 10-45 %), 50-\60 years (15 %, IQR 6-30 %), and 60-80 years (15 %, IQR 7-32 %) (Supplementary Appendix Fig. 1 ).
Associations of TILs with BCFI
Continuous TILs were associated with BCFI in univariable analysis, with an estimated HR for a 10-point change in TILs of 0.87 (95 % CI 0.79-0.95, P = 0.003). Multivariable analysis stratified by menopausal status and induction therapy type confirmed TILs as a prognostic marker for BCFI with an estimated HR of 0.87 (95 % CI 0.79-0.96, P = 0.006) after adjusting for age, nodal status, tumor size, and tumor grade. Consistent results were observed when TILs score was assessed as a binary variable (LPBC versus non-LPBC), with an estimated HR of 0.56 (95 % CI 0.33-0.94, P = 0.03) (HR = 0.61, 95 % CI 0.36-1.03, P = 0.06, in MVA) ( Fig. 2; Table 2 ).
Associations of TILs with DFS, DRFI, and OS
In multivariable analyses, continuous TILs were associated with DFS, DRFI, and OS, with an estimated HR for a 10- Table 2 ).
Predictive value of TILs
No TILs (LPBC)-by-treatment interaction was observed (interaction P values range 0.32-0.77), although patients with LPBC receiving CM-maintenance had greater reduction in the risk of breast cancer (HR 0.64, 95 % CI 0.23-1.78) versus No-CM than was observed among non-LPBC patients (HR 0.96, 95 % CI 0.67-1.40) ( Table 3) .
A STEPP analysis to explore the TILs-by-treatment interaction according to TILs score as a continuous measure, also indicated a possible greater beneficial effect of CM-maintenance for patients with higher TILs scores, with the differential treatment effect emerging when TILs score was about 30 % (Fig. 3) . Similar results were observed for DFS, DRFI, and OS (not shown).
Discussion
A growing body of evidence suggests that tumor immune response is associated with the clinical behavior of TNBC patients. Preclinical data suggest that both high-dose and low-dose chemotherapy regimens play an active role in modulating antitumor immunity. Anthracyclines are capable of sustaining an anticancer immune response via different mechanisms, such as recruitment and differentiation of antitumoral antigen-presenting cells or impairing of protumoral myeloid-derived suppressor cells [19] [20] [21] . Besides exerting its antitumoral effects through tumor angiogenesis inhibition [22, 23] , low-dose chemotherapy has also been shown to selectively deplete the immune-inhibitory T-reg
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No-CM N=307 subpopulation, eventually enhancing the effector T-cell antitumoral activity [24] . Along this line, low-dose cyclophosphamide plus gemcitabine administered metronomically has been reported to induce antitumor T-cell immunity in CT26 colon carcinoma-bearing mice [25] .
In the present study, we confirm that TILs-a surrogate of adaptive antitumor immunity-are a powerful prognostic indicator in the adjuvant setting for patients with TNBC, independent of age, nodal status, and tumor size. The TILs effect size in the cohort as a whole was remarkably similar to previous findings, with an adjusted overall survival HR 0.84 for each 10 % increment in TILs, as compared to 0.81-0.83 reported by Loi et al. [1, 2] and 0.76 by our group in a previous retrospective study [5] . We also provide further evidence that TILs WG guidelines have clinical validity and are highly reproducible: median TILs scores (21 %) and LPBC prevalence (18 %) were consistent with previous observations, and the interobserver agreement between two different readers was excellent (0.96 intraclass correlation coefficient).
The aforementioned data corroborate the notion that TILs are likely a prognostic marker in TNBC. However, their putative predictive value has not yet been elucidated, as most of the studies included patients treated with anthracycline-containing chemotherapy regimens, and we recently reported that TILs were also a prognostic factor in patients treated with CMF alone [5] . Likewise, the interaction of TILs with trastuzumab, originally postulated by (27) 144 (27) 27 (23) N ? C4 103 (16) 92 (17) 11 ( reporting that TILs were associated with survival in patients treated with chemotherapy alone, but not with chemotherapy plus trastuzumab [26] . Along this line, TILs have been recently reported to be a prognostic marker in patients with HER2-positive, early-stage breast cancer randomized in the neoadjuvant NeoALTTO trial to three treatment arms: trastuzumab, lapatinib, or the combination for six weeks followed by the addition of weekly paclitaxel for 12 weeks before surgery, followed by 3 cycles of fluorouracil, epirubicin, and cyclophosphamide after surgery. Although these data suggest a possible role of TILs in predicting benefit of anti-HER2 therapy, the authors did not exclude the likelihood that the prognostic effect of TILs could predominantly result from chemotherapy [27] .
In the present study, we explored the predictive role of TILs in patients randomized to receive low-dose CMmaintenance or No-CM after standard induction chemotherapy. The published results of the trial showed a trend toward a benefit for the triple-negative node-positive disease subgroup, prompting the authors to conclude that CM-maintenance should be further evaluated in high-risk patients with TNBC [10] . In the present study, the TILs-bytreatment interaction test did not show a statistically significant association between TILs and CM-maintenance, but we found that LPBC was associated with a greater observed magnitude of CM-maintenance treatment benefit than non-LBPC. Also, the exploratory STEPP analysis showed a possible greater effect of CM-maintenance for patients with higher TILs score, emerging as TILs score reached about 30 %. Collectively, these data suggest that further studies addressing whether TILs may identify a patient population possibly benefiting from low-dose maintenance chemotherapy strategies would be valuable. Our results confirm that TILs are a potent prognostic indicator in patients with TNBC, and that CM-maintenance may confer a greater clinical benefit for patients with LPBC. TILs tumor-infiltrating lymphocytes, LPBC Lymphocyte-predominant breast cancer (TILs score C50 %), BCFI breast cancer-free interval, DFS disease-free survival, DRFI distant recurrence-free interval, OS overall survival, HR hazards ratio, CI confidence interval * Adjusted for age, nodal status, tumor size, and tumor grade, stratified by menopausal status and induction chemotherapies Int-P LPBC-by-treatment interaction test P value, CM low-dose cyclophosphamide and methotrexate, TILs tumor-infiltrating lymphocytes, LPBC Lymphocyte-predominant breast cancer (TILs score C50 %), BCFI breast cancer-free interval, DFS disease-free survival, DRFI distant recurrence-free interval, OS overall survival, HR hazards ratio, CI confidence interval
